Abstract

LOPEZ BILBAO LA VIEJA, Ignacio. Nuevas opciones terapeúticas para el tratamiento de la Diabetes Mellitus Tipo 2. Cuad. - Hosp. Clín. [online]. 2005, vol.50, n.2, pp.74-83. ISSN 1562-6776.

Diabetes mellitus Type 2 is a health problem, due to the increase of its prevalence, which at the moment is 7% in our population., in order to avoid the complications that this disease presents it is necessary to maintain levels of Hbalc at 7%, fasting glicemia at levels below 110 mg/dL, and postprandial at 180 mg/dL two hours after meals, because a relation exists between cardiovascular morbimortality and postprandial hyperglicemia. This goal could be obtained by education of the patient, diet, and the use of drugs that at the present time are available among which we have the insulinosecretors like sulfonilureas, repaglinide and nateglinide that control postprandial glicemia. The sensibilization receptors which are metformin and glitazones; also the alfaglucosidase inhibitors, and at the present new antidiabetics are used whose therapeutic action is based on the increase of the action of the gastrointestinal hormones, that produce a diminution of the gastric emptying, insulin stimulation and glucagon inhibition, control of postprandial hyperglicemia and avoid weight gain. Among these we have the pramlintide that is an amyline analogue and exenamide that is an agonist of the GLP receptors (glucagon like peptide). All these can be used in combination with each other or with insulin obtaining better results.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )